Wellington Management Group LLP Makes New $546,000 Investment in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Wellington Management Group LLP purchased a new position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 60,751 shares of the biotechnology company's stock, valued at approximately $546,000.

Several other large investors also recently modified their holdings of AUPH. State Street Corp boosted its stake in Aurinia Pharmaceuticals by 2.3% in the 3rd quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company's stock valued at $21,587,000 after buying an additional 64,949 shares in the last quarter. Barclays PLC grew its holdings in shares of Aurinia Pharmaceuticals by 187.6% in the 3rd quarter. Barclays PLC now owns 219,331 shares of the biotechnology company's stock worth $1,607,000 after purchasing an additional 143,072 shares during the last quarter. Blue Trust Inc. increased its position in shares of Aurinia Pharmaceuticals by 3,041.4% during the 4th quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company's stock worth $57,000 after purchasing an additional 6,174 shares in the last quarter. Atria Wealth Solutions Inc. bought a new position in Aurinia Pharmaceuticals during the 4th quarter valued at about $135,000. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Aurinia Pharmaceuticals in the fourth quarter valued at about $9,662,000. 36.83% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded shares of Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, March 27th.

Insider Activity at Aurinia Pharmaceuticals

In related news, COO Matthew Maxwell Donley sold 65,902 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $527,216.00. Following the sale, the chief operating officer now directly owns 739,456 shares in the company, valued at $5,915,648. This trade represents a 8.18 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Greg Keenan sold 8,305 shares of the company's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $8.23, for a total transaction of $68,350.15. Following the completion of the sale, the insider now owns 153,484 shares of the company's stock, valued at approximately $1,263,173.32. This represents a 5.13 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 343,898 shares of company stock worth $2,753,094 over the last 90 days. Insiders own 4.30% of the company's stock.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ:AUPH traded up $0.09 during midday trading on Friday, reaching $7.76. The company's stock had a trading volume of 929,141 shares, compared to its average volume of 1,350,101. The business's fifty day simple moving average is $7.99 and its 200-day simple moving average is $8.11. The company has a market capitalization of $1.07 billion, a P/E ratio of -51.74 and a beta of 1.20. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. Aurinia Pharmaceuticals Inc. has a fifty-two week low of $4.77 and a fifty-two week high of $10.67.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.